Isosorbide Dinitrate — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.2-1 mg/kg	q8h	Duration: As needed; use with a nitrate-free interval of 8-12 hours to prevent tolerance Notes: Start at low end and titrate to effect. Monitor blood pressure and clinical signs.
Cat	PO	0.2-0.5 mg/kg	q8h	Duration: As needed; use with nitrate-free interval Notes: Use cautiously in cats; may cause hypotension.
Horse	PO	0.5-1 mg/kg	q12h	Duration: As needed; often used before exercise for EIPH Notes: Administer 30-60 minutes before exercise. Not approved for EIPH; use is off-label.

Clinical Indications & Species Uses

General Indications

Vasodilation in acute heart failure
Reduction of preload in congestive heart failure

Dog (Canine)

Congestive heart failure (adjunctive therapy)
Pulmonary hypertension
Angina pectoris (rarely used)
Hypertensive crises (off-label)

Cat (Feline)

Congestive heart failure (adjunctive therapy)
Pulmonary hypertension (off-label)

Horse (Equine)

Exercise-induced pulmonary hemorrhage (EIPH) (off-label)
Pulmonary hypertension (off-label)

Pharmacology & Mechanism of Action

Drug Class: Nitrate vasodilator | Pharmacological Group: Organic nitrate antianginal agent

Mechanism of Action: Isosorbide dinitrate is a prodrug that undergoes denitration to release nitric oxide (NO) in vascular smooth muscle cells. NO activates soluble guanylyl cyclase, increasing cyclic guanosine monophosphate (cGMP) levels, which in turn activates protein kinase G. This leads to dephosphorylation of myosin light chains and a reduction in intracellular calcium, causing vasodilation. At low doses, it predominantly dilates veins, reducing preload and ventricular wall tension; at higher doses, it dilates arteries, reducing afterload. In veterinary medicine, it is used primarily for its venodilatory effects to manage congestive heart failure and pulmonary hypertension.

Pharmacodynamics: Isosorbide dinitrate produces dose-dependent vasodilation with a greater effect on venous capacitance vessels than arterioles. It reduces left ventricular end-diastolic pressure and volume, decreases myocardial oxygen demand, and improves coronary blood flow in ischemic regions. In animals with heart failure, it reduces pulmonary capillary wedge pressure and alleviates pulmonary congestion. Tolerance develops with continuous use, requiring a nitrate-free interval (typically 8-12 hours) to maintain efficacy. The onset of action after oral administration is 15-30 minutes, with peak effects at 30-60 minutes.

⚡ Pharmacokinetics Summary

Absorption: Isosorbide dinitrate is well absorbed from the gastrointestinal tract after oral administration, but undergoes extensive first-pass hepatic metabolism, resulting in a bioavailability of approximately 20-30% in dogs. Sublingual administration bypasses first-pass metabolism, providing more rapid and complete absorption. The onset of action is 15-30 minutes for oral and 2-5 minutes for sublingual.

Distribution: The drug is widely distributed throughout the body, with a volume of distribution of approximately 2-4 L/kg in dogs. It crosses the placenta and is distributed into milk in small amounts. Protein binding is low, around 28%.

Metabolism: Isosorbide dinitrate is extensively metabolized in the liver by glutathione-S-transferase and cytochrome P450 enzymes to active metabolites, including isosorbide-2-mononitrate and isosorbide-5-mononitrate. The 5-mononitrate metabolite has a longer half-life and contributes to the pharmacologic effects. Metabolism is rapid, with a hepatic extraction ratio of about 0.6-0.8.

Excretion: Metabolites are excreted primarily in the urine (approximately 80-100%) as glucuronide conjugates, with a small amount excreted in feces. The elimination half-life of the parent drug is short (20-40 minutes in dogs), but the active metabolite isosorbide-5-mononitrate has a half-life of 4-6 hours.

Half-Life: Dog: 20-40 minutes (parent drug); 4-6 hours (active metabolite). Horse: approximately 30 minutes (parent drug).

Bioavailability: Oral: 20-30% in dogs due to first-pass metabolism; sublingual: higher, approximately 60-70%.

Protein Binding: Approximately 28% in dogs.

Available Formulations & Strengths

Oral Tablet 5 mg, 10 mg, 20 mg, 30 mg, 40 mg (PO)

Sublingual Tablet 2.5 mg, 5 mg, 10 mg (Sublingual)

Extended-Release Capsule 40 mg (PO)

Injectable Solution 0.1 mg/mL, 0.2 mg/mL (for IV infusion) (IV)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to isosorbide dinitrate or other nitrates
Severe hypotension (systolic blood pressure < 90 mmHg)
Cardiogenic shock or severe anemia
Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension
Increased intracranial pressure (e.g., head trauma)
Constrictive pericarditis or cardiac tamponade

Warnings & Clinical Precautions:

Use with caution in animals with hepatic or renal impairment.
Monitor blood pressure during dose titration.
Tolerance may develop with continuous use; provide a nitrate-free interval of 8-12 hours daily.
Do not use in animals with hypovolemia or dehydration.
Use with caution in animals with glaucoma (may increase intraocular pressure).
In horses, use with caution in animals with hypotension or bleeding disorders.
Not for use in food animals due to lack of withdrawal time data.

Adverse Effects & Reactions

Common:

Hypotension
Headache (in humans; may occur in animals)
Reflex tachycardia
Flushing
Dizziness

Serious / Severe:

Severe hypotension
Syncope
Methemoglobinemia (with high doses or prolonged use)
Worsening of angina (paradoxical)

Rare:

Allergic reactions
Gastrointestinal upset
Tolerance and cross-tolerance

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil)	Additive vasodilation and severe hypotension; contraindicated.	High
Other vasodilators (e.g., hydralazine, ACE inhibitors)	Additive hypotensive effects; monitor blood pressure.	Moderate
Beta-blockers	May reduce reflex tachycardia but can increase risk of bradycardia and hypotension.	Moderate
Diuretics	May enhance hypotension due to volume depletion.	Moderate
Heparin	Nitrates may decrease the anticoagulant effect of heparin.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Severe hypotension
Bradycardia or tachycardia
Syncope
Methemoglobinemia (cyanosis, dyspnea)
Seizures
Coma

Emergency Treatment Protocol: Discontinue the drug immediately. Provide supportive care: maintain airway, breathing, and circulation. Administer intravenous fluids for hypotension. For methemoglobinemia, administer methylene blue (1-2 mg/kg IV) if severe. Monitor vital signs and blood gases. In severe cases, consider activated charcoal if ingestion is recent.

Food Animal Withdrawal Times

Not approved for use in food animals; no withdrawal times established. Use in food animals is prohibited.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C) in a tightly closed container.

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep away from heat and open flames.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; used off-label in animals.

Extra-Label (Off-Label) Use: In the US, extra-label use in animals is permitted under AMDUCA if a valid veterinarian-client-patient relationship exists and no approved animal drug is available. However, use in food animals is prohibited due to lack of residue data.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Isosorbide dinitrate is a nitrate vasodilator used primarily as an adjunctive therapy for congestive heart failure in dogs and cats, particularly when pulmonary congestion or hypertension is present. It is not a first-line agent; ACE inhibitors, diuretics, and pimobendan are preferred. In horses, it has been used off-label for exercise-induced pulmonary hemorrhage, but evidence is limited. Due to the development of tolerance, a nitrate-free interval is essential. Blood pressure monitoring is recommended, especially during initial dosing. The drug should be used with caution in animals with hypotension or volume depletion. Sublingual administration may be used for rapid effect in acute situations. Always consider potential drug interactions, especially with PDE-5 inhibitors.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)